Drug Type Small molecule drug |
Synonyms Naltrexone Hydrochloride/Morphine sulfate hydrate, ALO-01, PF-06412528 + [2] |
Target |
Mechanism Opioid receptors antagonists(Opioid receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date US (13 Aug 2009), |
Regulation- |
Molecular FormulaC74H88Cl2N4O18S |
InChIKeyFFSBSYUGIGJQOU-INJDZLCSSA-N |
CAS Registry1131418-84-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Morphine Sulfate/Naltrexone Hydrochloride | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pain | US | 13 Aug 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cancer Pain | Phase 3 | CN | 05 Feb 2024 | |
Chronic Pain | Phase 3 | US | 01 Dec 2006 | |
Opioid abuse | Phase 1 | US | 01 Feb 2011 | |
Analgesia | Phase 1 | - | 01 Aug 2010 | |
Narcotic-Related Disorders | Phase 1 | - | 01 Aug 2010 | |
Opioid-Related Disorders | Phase 1 | - | 01 Aug 2010 |
Phase 3 | 467 | sfobwaszom(jbpdtpmsmt) = xqwiqzwhfm uslfosxrhz (isuhahwsrb, vtylmwleam - sladtddnjc) View more | - | 29 Oct 2009 |